HomeCompareCWYUF vs MRK

CWYUF vs MRK: Dividend Comparison 2026

CWYUF yields 7.03% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $21.6K in total portfolio value· pulled ahead in Year 5
10 years
CWYUF
CWYUF
● Live price
7.03%
Share price
$19.03
Annual div
$1.34
5Y div CAGR
3.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.2K
Annual income
$1,752.13
Full CWYUF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CWYUF vs MRK

📍 MRK pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCWYUFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CWYUF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CWYUF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CWYUF
Annual income on $10K today (after 15% tax)
$597.14/yr
After 10yr DRIP, annual income (after tax)
$1,489.31/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $6,839.10/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CWYUF + MRK for your $10,000?

CWYUF: 50%MRK: 50%
100% MRK50/50100% CWYUF
Portfolio after 10yr
$46.0K
Annual income
$5,775.13/yr
Blended yield
12.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CWYUF
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
0.8
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CWYUF buys
0
MRK buys
0
No recent congressional trades found for CWYUF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCWYUFMRK
Forward yield7.03%2.76%
Annual dividend / share$1.34$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR3.9%32.7%
Portfolio after 10y$35.2K$56.8K
Annual income after 10y$1,752.13$9,798.13
Total dividends collected$11.9K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CWYUF vs MRK ($10,000, DRIP)

YearCWYUF PortfolioCWYUF Income/yrMRK PortfolioMRK Income/yrGap
1$11,430$729.92$11,206$366.19+$224.00CWYUF
2$13,040$810.12$12,650$502.35+$390.00CWYUF
3$14,850$897.47$14,407$694.19+$443.00CWYUF
4$16,882$992.45$16,585$967.82+$297.00CWYUF
5← crossover$19,160$1,095.56$19,342$1,363.89$182.00MRK
6$21,708$1,207.32$22,913$1,947.19$1.2KMRK
7$24,556$1,328.28$27,662$2,823.89$3.1KMRK
8$27,734$1,459.01$34,159$4,173.35$6.4KMRK
9$31,275$1,600.08$43,337$6,308.80$12.1KMRK
10$35,217$1,752.13$56,776$9,798.13$21.6KMRK

CWYUF vs MRK: Complete Analysis 2026

CWYUFStock

SmartCentres Real Estate Investment Trust is one of Canada's largest fully integrated REITs, with a best-in-class portfolio featuring 166 strategically located properties in communities across the country. SmartCentres has approximately $10.4 billion in assets and owns 33.8 million square feet of income producing value-oriented retail space with 97.4% occupancy, on 3,500 acres of owned land across Canada. SmartCentres continues to focus on enhancing the lives of Canadians by planning and developing complete, connected, mixed-use communities on its existing retail properties. A publicly announced $11.9 billion intensification program ($5.4 billion at SmartCentres' share) represents the REIT's current major development focus on which construction is expected to commence within the next five years. This intensification program consists of rental apartments, condos, seniors' residences and hotels, to be developed under the SmartLiving banner, and retail, office, and storage facilities, to be developed under the SmartCentres banner. SmartCentres' intensification program is expected to produce an additional 59.3 million square feet (27.9 million square feet at SmartCentres' share) of space, 27.1 million square feet (12.3 million square feet at SmartCentres' share) of which has or will commence construction within next five years. From shopping centres to city centres, SmartCentres is uniquely positioned to reshape the Canadian urban and urban-suburban landscape. Included in this intensification program is the Trust's share of SmartVMC which, when completed, is expected to include approximately 11.0 million square feet of mixed-use space in Vaughan, Ontario. Construction of the first five sold-out phases of Transit City Condominiums that represent 2,789 residential units continues to progress. Final closings of the first two phases of Transit City Condominiums began ahead of budget and ahead of schedule in August 2020 and as at September 30, 2020, 766 units (representing approximately 70% of all 1,110 units in the first and second phases) had closed with the balance of units expected to close before year end. In addition, the presold 631 units in the third phase along with 22 townhomes, all of which are sold out and currently under construction, are expected to close in 2021. The fourth and fifth sold-out phases representing 1,026 units are currently under construction and are expected to close in 2023.

Full CWYUF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CWYUF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CWYUF vs SCHDCWYUF vs JEPICWYUF vs OCWYUF vs KOCWYUF vs MAINCWYUF vs JNJCWYUF vs ABBVCWYUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.